November 15, 2024 — GenScript Biotech announced that its CDMO subsidiary, ProBio, has licensed its PD-1 new molecular entity (NME) to LaNova Medicines, which recently entered into an agreement with Merck to advance treatment.

LaNova utilised ProBio's PD-1 molecule to develop its PD-1/VEGF bispecific antibody, a key component of the LM-299 program. Following LaNova's recent agreement with Merck, GenScript projects that ProBio's partnership with LaNova could generate significant revenue for ProBio, as LaNova Medicines has entered into an exclusive agreement with Merck & Co., Inc for LM-299 for a reported $3.3 billion.

This agreement underlines ProBio’s commitment in immuno-oncology as well as its capability to combine molecular innovation with advanced contract manufacturing services.